These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 21323393)

  • 1. Managing cognitive dysfunction through the continuum of Alzheimer's disease: role of pharmacotherapy.
    Delrieu J; Piau A; Caillaud C; Voisin T; Vellas B
    CNS Drugs; 2011 Mar; 25(3):213-26. PubMed ID: 21323393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholinesterase inhibitors for Alzheimer's disease.
    Birks J
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD005593. PubMed ID: 16437532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Alzheimer's disease in the long-term-care setting.
    Smith DA
    Am J Health Syst Pharm; 2009 May; 66(10):899-907. PubMed ID: 19420308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationalizing therapeutic approaches in Alzheimer's disease.
    Grossberg GT
    CNS Spectr; 2005 Nov; 10(11 Suppl 18):17-21. PubMed ID: 16273026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
    Thancharoen O; Limwattananon C; Waleekhachonloet O; Rattanachotphanit T; Limwattananon P; Limpawattana P
    Drugs Aging; 2019 May; 36(5):435-452. PubMed ID: 30937879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].
    Sicras-Mainar A; Vergara J; Leon-Colombo T; Febrer L; Rejas-Gutierrez J
    Rev Neurol; 2006 Oct 16-31; 43(8):449-53. PubMed ID: 17033976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.
    Thompson S; Lanctôt KL; Herrmann N
    Expert Opin Drug Saf; 2004 Sep; 3(5):425-40. PubMed ID: 15335298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
    Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M
    J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study.
    Scharre DW; Vekeman F; Lefebvre P; Mody-Patel N; Kahler KH; Duh MS
    Drugs Aging; 2010 Nov; 27(11):903-13. PubMed ID: 20964464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
    Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L
    J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective pharmacological management of Alzheimer's disease.
    Atri A
    Am J Manag Care; 2011 Nov; 17 Suppl 13():S346-55. PubMed ID: 22214392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donepezil for dementia due to Alzheimer's disease.
    Birks JS; Harvey R
    Cochrane Database Syst Rev; 2003; (3):CD001190. PubMed ID: 12917900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease.
    Standridge JB
    Clin Ther; 2004 May; 26(5):615-30. PubMed ID: 15220008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donepezil and memantine for moderate-to-severe Alzheimer's disease.
    Howard R; McShane R; Lindesay J; Ritchie C; Baldwin A; Barber R; Burns A; Dening T; Findlay D; Holmes C; Hughes A; Jacoby R; Jones R; Jones R; McKeith I; Macharouthu A; O'Brien J; Passmore P; Sheehan B; Juszczak E; Katona C; Hills R; Knapp M; Ballard C; Brown R; Banerjee S; Onions C; Griffin M; Adams J; Gray R; Johnson T; Bentham P; Phillips P
    N Engl J Med; 2012 Mar; 366(10):893-903. PubMed ID: 22397651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.
    Kavirajan H; Schneider LS
    Lancet Neurol; 2007 Sep; 6(9):782-92. PubMed ID: 17689146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).
    Knapp M; King D; Romeo R; Adams J; Baldwin A; Ballard C; Banerjee S; Barber R; Bentham P; Brown RG; Burns A; Dening T; Findlay D; Holmes C; Johnson T; Jones R; Katona C; Lindesay J; Macharouthu A; McKeith I; McShane R; O'Brien JT; Phillips PPJ; Sheehan B; Howard R
    Int J Geriatr Psychiatry; 2017 Dec; 32(12):1205-1216. PubMed ID: 27739182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis.
    Kobayashi H; Ohnishi T; Nakagawa R; Yoshizawa K
    Int J Geriatr Psychiatry; 2016 Aug; 31(8):892-904. PubMed ID: 26680338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapeutic strategies in the treatment of severe Alzheimer's disease.
    Deardorff WJ; Grossberg GT
    Expert Opin Pharmacother; 2016 Sep; 17(13):1789-800. PubMed ID: 27450461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT.
    Jones R; Sheehan B; Phillips P; Juszczak E; Adams J; Baldwin A; Ballard C; Banerjee S; Barber B; Bentham P; Brown R; Burns A; Dening T; Findlay D; Gray R; Griffin M; Holmes C; Hughes A; Jacoby R; Johnson T; Jones R; Knapp M; Lindesay J; McKeith I; McShane R; Macharouthu A; O'Brien J; Onions C; Passmore P; Raftery J; Ritchie C; Howard R;
    Trials; 2009 Jul; 10():57. PubMed ID: 19630974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease.
    Deardorff WJ; Grossberg GT
    Drug Des Devel Ther; 2016; 10():3267-3279. PubMed ID: 27757016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.